Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ-B3456 Phase I in NSCLC
NCT03754244Phase 1Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQ-B3456 in non-small cell lung cancer (NSCLC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Dose-Limiting Toxicities. Started Sep 2020; status: terminated.
02
Drugs
TQ-B3456
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03754244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03754244.